Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Department of Laboratory Medicine, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Theranostics. 2021 Jan 1;11(4):1753-1762. doi: 10.7150/thno.53438. eCollection 2021.
Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), remains a fatal disease with few efficacious treatments. The Hippo signaling pathway, an evolutionarily conserved signaling module, plays critical roles in tissue homeostasis, organ size control and tumorigenesis. The transcriptional coactivator yes-associated protein (YAP), a major downstream effector of the Hippo pathway, is associated with various human cancers including PDAC. Considering its importance in cancer, YAP is emerging as a promising therapeutic target. In this review, we summarize the current understanding of the oncogenic role and regulatory mechanism of YAP in PDAC, and the potential therapeutic strategies targeting YAP.
胰腺癌，尤其是胰腺导管腺癌（PDAC），仍然是一种致命的疾病，几乎没有有效的治疗方法。Hippo 信号通路是一种进化上保守的信号模块，在组织稳态、器官大小控制和肿瘤发生中发挥着关键作用。转录共激活因子 yes 相关蛋白（YAP）是 Hippo 通路的主要下游效应因子，与包括 PDAC 在内的多种人类癌症有关。鉴于其在癌症中的重要性，YAP 正成为一个有前途的治疗靶点。在这篇综述中，我们总结了 YAP 在 PDAC 中的致癌作用和调控机制的最新认识，以及针对 YAP 的潜在治疗策略。
